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Abstract
Background: Cancer cells are believed to arise primarily from stem cells. CD44
+/CD24
- have been identified as
markers for human breast cancer stem cells. Although, HER2 is a well known breast cancer oncogene, the
mechanisms of action of this gene are not completely understood. Previously, we have derived immortal (M13SV1),
weakly tumorigenic (M13SV1R2) and highly tumorigenic (M13SV1R2N1) cell lines from a breast epithelial cell type
with stem cell phenotypes after successive SV40 large T-antigen transfection, X-ray irradiation and ectopic
expression of HER2/C-erbB2/neu. Recently, we found that M13SV1R2 cells became non-tumorigenic after growing
in a growth factor/hormone-deprived medium (R2d cells).
Results: In this study, we developed M13SV1R2N1 under the same growth factor/hormone-deprived condition
(R2N1d cells). This provides an opportunity to analyze HER2 effect on gene expression associated with
tumorigenesis by comparative study of R2d and R2N1d cells with homogeneous genetic background except HER2
expression. The results reveal distinct characters of R2N1d cells that can be ascribed to HER2: 1) development of
fast-growing tumors; 2) high frequency of CD44
+/CD24
- cells (~50% for R2N1d vs. ~10% for R2d); 3) enhanced
expression of COX-2, HDAC6 mediated, respectively, by MAPK and PI3K/Akt pathways, and many genes associated
with inflammation, metastasis, and angiogenesis. Furthermore, HER2 expression can be down regulated in non-
adhering R2N1d cells. These cells showed longer latent period and lower rate of tumor development compared
with adhering cells.
Conclusions: HER2 may induce breast cancer by increasing the frequency of tumor stem cells and upregulating
the expression of COX-2 and HDAC6 that play pivotal roles in tumor progression.
Background
Breast cancers and other cancers are believed to arise pri-
marily from stem cells [1] through a series of genetic and
epigenetic alterations facilitated by mechanisms of tumor
initiation, promotion and genomic instability [2]. One of
the best known breast cancer oncogenes is HER2 (also
known as neu, ErbB-2, and NGL) which belongs to the
epidermal growth factor receptor (EGFR) family [3,4] and
encodes an 185 kDa transmembrane receptor tyrosine-
kinase [5-7]. Human HER2 oncogene and its p185
HER2/neu
oncoprotein are overexpressed in 20-30% of invasive
breast cancers [8,9] and have been associated with cyto-
toxic and endocrine drug therapy resistance [10]. The
mechanisms of action of HER2 over-expression that cause
tumor development and enhance the intrinsic metastatic
potential of breast cancer [11] are not completely under-
stood. However, few major mechanisms have been
reported. First, HER2 could regulate cyclooxygenase
(COX)-2 [12] and elevated COX-2 could induce many
tumorigenic effects such as tumor invasion, angiogenesis,
suppression of host immunity, resistance to apoptosis
[13-15] and epithelial to mesenchymal transition (EMT)
[16]. Second, p185
HER2/neu could phosphorylate and acti-
vate major signalling pathways such as phosphatidylinosi-
tol-3-kinase (PI3K/Akt) and mitogen-activated protein
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growth and metastasis [10,17,18]. Conversely, anti-HER2
antibody, Herceptin, could inhibit PI3K/Akt and result in
up-regulation of p27, down-regulation of cyclin D1 and
antitumor action [19]. Thirdly, HER2 has been reported to
i n c r e a s et h es i z ea n df r e q u e n c yo fm a m m o s p h e r e st h a t
contain breast epithelial progenitor cells and to expand
normal mammary epithelial cells that express the stem
cell marker, aldehyde dehydrogenase (ALDH) [20].
Furthermore, ectopic expression of HER2 in human mam-
mary carcinoma cells could increase ALDH-positive cells,
indicating that HER2 could enhance the frequency of both
n o r m a la n dc a n c e rs t e mc e l l s[ 2 0 ] .
We have previously reported the isolation of a human
breast epithelial cell type (Type-1 HBEC) from reduction
mammoplasty of healthy women with stem cell character-
istics [21]. These cells are characterized by deficiency in
gap-junctional intercellular communication [21], the abil-
ity to form budding and ductal organoids on Matrigel
[22], the expression of luminal epithelial cell markers (i.e.
epithelial membrane antigen and cytokeratin 18) [21],
estrogen receptor-alpha (ERa) [23] and the stem cell pluri-
potency gene Oct-4 [24], similar to the phenotypes of
breast carcinoma cells such as the MCF-7 cell line.
Furthermore, Type-1 HBECs were highly susceptible to
telomerase activation and immortalization following SV40
large T-antigen transfection [25] which is known to inacti-
vate p53 and Rb as well as to transactivate a CCAAT box
binding factor (CBF/cdc2) [26,27]. Both changes have
been reported for human breast cancer. These immortal
cells (M13SV1) can be further transformed to weakly
tumorigenic (M13SV1R2) and highly tumorigenic cells
(M13SV1R2N1) by successive X-ray irradiation and ecto-
pic expression of C-erbB2/neu [28]. Recently, we found
that M13SV1R2 cells became non-tumorigenic after grow-
ing in a growth factor/hormone-deprived medium for >10
passages (referred to as R2d cells) [16]. Unlike M13SV1R2
cells, these R2d cells contain CD44
+/CD24
- cells pre-
viously identified as breast cancer stem cells [29] and were
responsive to estrogen for cell growth and tumor develop-
ment [16]. In this study, we developed M13SV1R2N1
under the same growth factor/hormone-deprived condi-
tion (referred to as R2N1d cells). This provides an oppor-
tunity to analyze unambiguously the effects of HER2 on
tumor development and gene expressions underlying
tumorigenic mechanisms by comparative study of R2d
and R2N1d cells with homogeneous genetic background
under same cell culture condition.
Results
Development of R2N1d cells
In order to investigate HER2 effect on tumor develop-
ment and gene expression, M13SV1R2N1 cells were cul-
tured under similar condition as R2d cells, i.e. in MSU-1
medium [21] without growth factors/hormones except
5% FBS for more than 10 passages, (referred to as
R2N1d) (Figure 1A). Morphologically, R2N1d cells were
more heterogeneous, i.e. increased intercellular separa-
tion and scattering of cells and the formation of pseudo-
podia (Figure 1A). Similar to parental M13SV1R2N1
cells, R2N1d cells expressed ERa and HER2 by immu-
nocytochemical study (Figure 1B).
R2N1d cells expressed stem cell-related genes
The Notch signaling pathway is implicated in the regula-
tion of cell differentiation and self-renewal of mammary
stem cells. Over-expression of the active form of Notch 4
inhibits differentiation of breast epithelial cells [30].
Musashi-1 (Msi-1) is a positive regulator of Notch signal-
ing, and both Msi-1 and Notch 1 are key regulators of
asymmetrical cell division in human breast epithelial
stem cells [31]. We have examined whether R2N1d cells
express genes involved in stem cell function and self-
renewal, i.e. Oct-4 [24] and Notch pathway [32] by flow
cytometric analysis. The results show that R2N1d cells
expressed the stem cell pluripotency gene, Oct-4,
(99.37%) and the Notch pathway-related genes, Notch1
(99.95%), Notch4 (99.89%) and Msi1 (100%) (Figure 1C).
The expression of these genes in R2N1d was similar to
R2d cells (data not shown). Similar to parental normal
Type 1 HBECs [21,22,24] and immortal R2d [16] cells, as
well as human breast carcinoma cells such as MCF-7, the
R2N1d cells expressed Oct-4 and luminal epithelial cells
markers, cytokeratin 18 and 19 (Figure 1C).
Comparison of gene expression profiles between R2d
cells and R2N1d cells
R2d and R2N1d cells were derived from the same paren-
tal cell. Their cellular contexts are presumably similar
except the integration and expression of the HER2/neu
gene in R2N1d cells. In order to examine the mechanism
of action of HER2 in human breast tumor development,
we analyzed the differential gene expression profiles
between R2d and R2N1d cells, using the HumanWG-6
BeadChip. The mRNA expression of R2d and R2N1d
cells were compared in a scatter plot. They presented
similar patterns in Pearson correlation R
2 of 0.7821. Out
of the genes screened, 3289 genes in R2N1d cells were
found to be upregulated by more than 5-folds in compar-
ison with R2d cells, while none was found to be down-
regulated by more than 5-folds. Further analysis of the
total genes by MetaCore reveals high expression of genes
involved in cytoskeleton remodeling, cell adhesion and
cell cycle progression in the top ten GeneGo pathway
maps (Figure 2A). There was elevated expression of
genes related to transcription, translation and cell cycle
processes among the top ten GeneGo process networks
(Figure 2A). For investigation of HER2 function in
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cell adhesion, metastasis, inflammation, angiogenesis and
migration. In these categories of function, many genes
were elevated in R2N1d cells: 51, 135, 79, 21 and 12
genes, respectively, for cell adhesion, metastasis, inflam-
mation, angiogenesis and migration (see Additional file 1,
Table S1). There are eight genes that are at once corre-
lated with metastasis, inflammation and angiogenesis, i.e.
TNFRSF12A, CEACAM1, PLAU, HIF1A, IL8, HMOX1,
VEGFC and IL1B. Two genes are simultaneously corre-
lated with adhesion, metastasis, and migration, i.e. CD44
and LAMC1 (Figure 2B). The altered expression of some
selected genes was subsequently confirmed by q-PCR.
The HER2 overexpression in R2N1d cells was also
detected in this study (Table 1).
HER2 overexpression enhanced cyclooxygenase-2
expression through MAPK pathway
In literature, COX-2 overexpression is found in many dif-
ferent human cancers including breast cancer [33]. Over-
expression of HER2 was associated with increased level
of COX-2 [34]. Therefore, we carried out experiments to
Figure 1 Derivation of a tumorigenic cell line (R2N1d) and characteristics of R2N1d cells. A, a diagram showing the development of R2d
cells which are non-tumorigenic and R2N1d cells which are highly tumorigenic. Both R2d and R2N1d cells were derived from the same
immortal cell line M13SV1 and cultured for >10 passages under same cell culture condition before experiment using MSU-1 medium without
growth factors and hormones (except 5% FBS). B, expression of ER-a and HER2 in R2N1d cells by immunocytochemical staining (green
fluorescence). Cell nuclei were stained with DAPI and recognized as blue fluorescence (top figure, image observed under fluorescence
microscope; bottom figure, the mergence of fluorescence and phase images, scale bar = 100 μm). C, R2N1d cells were labelled with antibodies
against CK-18, CK-19, Msi1, Notch-1, Notch-4 and Oct-4 for immunophenotyping by flow cytometric analysis. The open histograms indicate
background signal and shaded histograms showing positive reactivity.
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COX-2 in R2N1d cells. By qPCR analysis, the mRNA
level of COX-2 was, indeed, significantly increased in
R2N1d cells (2.6-folds) compared to R2d cells (Table 1).
The HER2 effect on up-regulation of COX2 expression is
confirmed by western blot analysis as shown in Figure 3B
(R2N1d, lane 1 and R2N1d treated with AG825, lane 4)
or when R2N1d (Figure 3B, lane 1) and R2d cells (Figure
3A, lane 1 in reference 16) are compared (Additional file
2, Figure S1). Furthermore, by flow cytometric analysis,
the treatment with a selective ATP-competitive inhibitor
of the tyrosine kinase activity of HER2 (AG825, 25 μM)
partially negated the expression of COX-2. A highly
selective inhibitor of MAPK/ERK (U0126, 10 μM) and a
selective inhibitor of COX-2 (NS398, 100 μM) also par-
tially negated the expression of COX-2 (Figure 3A). This
HER2 mediated COX-2 expression through MAPK path-
w a yw a sc o n f i r m e db yw e s t e r nb l o t t i n g .A ss h o w ni n
Figure 3B, AG825 and U0126 caused a marked decrease
in COX-2 expression in a time-dependent manner in
R2N1d cells; as expected, NS398 treatment blocked the
expression of COX-2 protein. In contrast, all these 3
inhibitors did not modulate the expression of COX-1
(Figure 3B). Overall, these experiments provide evidence
that HER2 could up-regulate COX-2 expression through
MAPK pathway in R2N1d cells.
HDAC6 as a HER2-regulated gene in R2N1d cells
Histone deacetylases (HDACs) have been linked to
pathogenesis of cancer [35]. Among them, HDAC6 has
been shown to be required for efficient oncogenic trans-
formation and tumor formation [36,37]. HDAC6 could
Figure 2 Functional analysis of genes significantly up-regulated in R2N1d cells compared with R2d cells. A, genes involved in top ten of
GeneGo pathway maps and top ten GeneGo process networks by MetaCore analysis. B, number of up-regulated genes belongs to 5 functional
categories. Eight genes are at once correlated with metastasis, inflammation and angiogenesis, i.e. TNFRSF12A, CEACAM1, PLAU, HIF1A, IL8, HMOX1,
VEGFC and IL1B, whereas two genes are correlated with adhesion, metastasis, and migration, i.e. CD44 and LAMC1.
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migration [37-39]. A study was carried out to determine
if HER2 could affect the expression of HDAC6 in
R2N1d cells which express the HDAC6 by flow cyto-
metric analysis (99.85%) (Figure 3C). By western blotting
analysis, we detected a decrease of HDAC6 protein after
24 h treatment with the HER2 inhibitor, AG825, indi-
cating that the expression of HDAC6 is regulated by
HER2 in R2N1d cells. The relative amount of acetylated
alpha-tubulin was found to be inversely correlated with
the expression of HDAC6 (Figure 3D). The effect of
HER2 on HDAC6 expression was also revealed by the
higher expression of this gene in R2N1d compared with
R2d cells (2.41 fold) (last listing in Additional file 1,
Table S1) and by RT-PCR analysis (Figure 3E).
PI3K inhibitor, LY294002, repressed the expression of
HDAC6 in R2N1d cells
HDAC6 could contribute to tumorigenesis by facilitating
the activation of PI3K/Akt pathway [34]. It is, however,
not clear if the expression of HDAC6 could be affected by
PI3K activation. By western blotting analysis, we detected
a decrease of HDAC6 protein expression in R2N1d cells
after 24 h treatment with the PI3K inhibitor, LY294002
(10 μM), while relative amount of acetylated alpha-tubulin
was inversely correlated with the expression of HDAC6
(Figure 3D). The results indicate that HDAC6 expression
could be regulated by PI3K/Akt activity.
HER2 overexpression increased invasiveness
We have compared the invasion ability of R2d cells,
R2N1d cells and R2N1d cells treated with HER2 inhibi-
tor, AG825. The results reveal that R2N1d cells had a
2.2-fold higher invasion ability compared to R2d cells
and R2N1d cells treated with AG825 cells had a 2.5-fold
lower invasion ability compared to R2N1d cells without
AG825 treatment (Figure 3F), indicating that HER2
enhanced the cell invasion ability.
HER2 converted non-tumorigenic R2d cells into highly
tumorigenic R2N1d cells
In our tumorigenesis study, different numbers of R2d or
R2N1d cells (1 × 10
5,1×1 0
6 or 1 × 10
7)w e r es u b c u t a -
neously injected into immune-deficient mice for tumor
development. Those mice inoculated with low or high
number (1 × 10
5 or 1 × 10
7 cells) of R2d cells failed to
develop tumor 24 weeks after inoculation (Figure 4A). In
contrast, R2N1d cells, developed visible and palpable
Table 1 Comparison of fold increase of RNA transcript between R2N1d and R2d cells by qPCR analysis
Gene Name Symbol Description Up-/Down-
Regulation
AACT/ACT SERPINA3 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 12.50
HER2/HER2 ERBB2 V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene
homolog (avian)
6.38
ASBABP2/DIPLA1 PAPPA Pregnancy-associated plasma protein A, pappalysin 1 3.91
AIS/DHTR AR Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular
atrophy; Kennedy disease)
3.50
TSP2 THBS2 Thrombospondin 2 3.30
CORNIFIN/GADD33 SPRR1B Small proline-rich protein 1B (cornifin) 3.14
COX-2/COX2 PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 2.59
IBP2/IGF-BP53 IGFBP2 Insulin-like growth factor binding protein 2, 36kDa 2.49
CD271/Gp80-
LNGFR
NGFR Nerve growth factor receptor (TNFR superfamily, member 16) 2.41
Cyclin A1 CCNA1 Cyclin A1 2.36
ARMD9/ASP C3 Complement component 3 2.22
BCEI/D21S21 TFF1 Trefoil factor 1 2.13
STC-2/STCRP STC2 Stanniocalcin 2 -2.21
BAG-1 BAG1 BCL2-associated athanogene -2.34
GIG8/ID2A ID2 Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein -2.48
DKFZp686A04236/
HMG1
HMGB1 High-mobility group box 1 -2.54
CD49f/ITGA6B ITGA6 Integrin, alpha 6 -2.56
DKFZp686N23123/
ER
ESR1 Estrogen receptor 1 -2.64
Beta-NGF/HSAN5 NGF Nerve growth factor (beta polypeptide) -2.68
GIF/GIFB MT3 Metallothionein 3 -3.88
CBF-A/CBF-B NFYB Nuclear transcription factor Y, beta -4.04
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10
5 cells. Tumors developed from different numbers of
R2N1d cells were harvested at 4 weeks after inoculation
for quantitative measurement of tumors and pathological
analysis. The results show that tumor sizes were closely
dependent on numbers of R2N1d cells initially inoculated,
i.e. 100 ± 18 mg, 225 ± 36 mg, 528 ± 82 mg, respectively
for 1 × 10
5,1×1 0
6 ,1×1 0
7 cells inoculated (Figure 4A).
These tumors were processed for immunohistochemical
study. Histological sections of the resected tumor revealed
Figure 3 HER2 effects on COX-2 and HDAC6 expression and cell invasion. A, the effect of AG825 (a HER2 tyrosine kinase inhibitor, 25 μM),
U0126 (a highly selective inhibitor of MAPK/ERK kinase, 10 μM) or NS398 (a COX-2 inhibitor, 100 μM) treatment on COX-2 protein expression in
R2N1d cells by flow cytometry analysis. B, the effect of AG825, U0126 or NS398 treatment on COX-1 and COX-2 expression in R2N1d cells by
western blotting analysis. C, the expression of HDAC6 in R2d and R2N1d cells by flow cytometry analysis. D, the effect of AG825 (25 μM) and
LY294002 (10 μM) (a PI3K inhibitor) treatment on HDAC6 expression in R2N1d cells by western blotting analysis. E, the effect of AG825 (25 μM)
treatment for 24 hr on HER2 and HDAC6 expression in R2d and R2N1d cells by RT-PCR analysis. F, the effect of HER2 inhibitor, AG825 (25 μM),
treatment for 24 hr on invasion ability of R2N1d cells, assayed by using the invasion chamber. R2d cells were also included in the experiment.
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Page 6 of 15Figure 4 Tumorigenicity of R2d and R2N1d cells, and genes expressed by tumors developed by R2N1d cells. A, the development of
tumors in immune-deficient mice after inoculation with different numbers of R2d or R2N1d cells (1 × 10
5,1×1 0
6 or 1 × 10
7 cells per site) for
4 months (R2d) or 4 weeks (R2N1d). The average size of tumors for each treatment are also determined. B, histological sections of resected
tumor revealed sheets of polygonal cells with high nucleus/cytoplasm (N/C) ratio. C, these tumor cells expressed Ki67 (90%), VEGF (score 4),
COX-2 (score 4) and MMP-9 (score 4). The length of the scale bar of these photos is 100 μm.
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plasmic (N/C) ratio, hyperchromasia and pleiomorphism.
There were areas where tumor cells invaded neighboring
tissue (Figure 4B). These tumor cells showed the expres-
sion of Ki-67 (90%), VEGF (score 4), COX-2 (score 4) and
MMP-9 (score 4) that are known to be expressed in inva-
sive and metastatic tumors (Figure 4C). These results
clearly show that R2N1d cells with HER2 overexpression
were highly tumorigenic, whereas R2d cells were non-
tumorigenic.
High frequency of R2N1d cells expressed breast cancer
stem cell markers
Since cancer stem cells initiate and sustain tumor growth,
these cells are also considered as targets for cancer ther-
apy. For breast cancer, CD44
+/CD24
-/low [29] and alde-
hyde dehydrogenase (ALDH) [40] have been reported as
markers for breast cancer stem cells. We examined the
expression of CD44
+/CD24
-/low in R2d and R2N1d cells by
flow cytometric analysis. The results revealed a very high
frequency of CD44
+/CD24
-/low cells in R2N1d cells (50%)
compared to that in R2d cells (10%) (Figure 5A). It is also
noted that a subpopulation of CD44
high cells (Figure 5A,
R1 region) appeared in R2N1d cell culture (1.5%). The
results of this study clearly show that a major function of
HER2 is to increase the frequency of CD44
+/high/CD24
-
cancer stem cells.
Non-adherent R2N1d cells derived from adherent
monolayer culture lost HER2 and CD44
+/CD24
- expression
CD44
+/CD24
- cells were sorted out from R2N1d cells
by flow cytometry. These cells tend to show contact-
insensitive growth (piling up) in monolayer and gave
rise to non-adherent cells in suspension in extended
growth (Figure 5B).
Experiments were carried out to compare gene expres-
sion of adherent and non-adherent R2N1d cells as well
as reattached non-adherent cells after replating. By flow
cytometric analysis and by western blotting, the results
indicate that, while Oct-4 expressions were comparable
in the 3 different populations of cells, the HER2 expres-
sion was significantly reduced in non-adherent cells
(Figure 5C, D and 5E). After incubation of non-adherent
R2N1d cells for 3 weeks, a few of these suspended cells
re-attached and proliferated (colony-forming efficiency
was 3/15000). These re-attached cells were found to
express HER2 and Oct-4 similar to their parental adher-
ent cells (Figure 5C, D and 5E).
Results presented previously (Figure 3D) show that
HER2 and PI3K/Akt activity regulate the expression
HDAC6. Consistent with this function, we found that
adherent and reattached R2N1d cells expressed HER2 as
well as AKT1 and HDAC6, whereas non-adherent
R2N1d cells in suspension lost the expression of these
3 markers (Figure 5D). The expression of CD44
+/CD24
-
in non-adherent R2N1d cells was found to be dramati-
cally reduced compared to adherent cells (Additional file
3, Figure S2), reaffirming the regulation of CD44
+/CD24
-
expression by HER2.
HER2-negative R2N1d cells from suspension formed
HER2 positive tumor at lower frequency and with
longer latent period
Since we have the 3 different populations of R2N1d cells
developed under different culture condition and with dif-
ferent expression of HER2 (i.e. adherent, non-adherent
and reattached non-adherent cells), it is important to
know if they differ in tumorigenicity in immune-deficient
mice. The results show that both adherent and re-attached
R2N1d cells developed tumors in 2 weeks with 1 × 10
7
cells. In contrast, the non-adherent R2N1d cells in cell
suspension did not form palpable tumors until 6 months
post-inoculation of the same number of cells (1 × 10
7
cells). The tumor-forming frequency of the non-adherent
cells was also lower (4/6) compared with adherent and
reattached cells (6/6), examined 6 months after subcuta-
neous injection of cells (Figure 6 and 7). All these newly
formed tumors developed by the 3 types of cells expressed
HER2 by immunohistochemical study (Figure 6A). These
results reaffirmed the important role of HER2 in tumor
development.
Discussion and Conclusions
HER2 as an important breast cancer oncogene is well
known from the frequent amplification or overexpres-
sion of this gene in aggressive breast tumors [8,9] and
the efficacy of anti-HER2 antibody, Herceptin, in treat-
ment of breast cancer with HER2 overexpression [41].
Although some functions and mechanisms of HER2 in
breast tumor development have been delineated, the
exact mechanisms of action of this gene have not been
completely understood. By comparison of phenotypic
differences of two cell lines derived from a common
breast epithelial stem cell with homogeneous cellular
context but differing in HER2 expression under same
cell culture condition, we believe the results of this
study should reveal more convincing and unambiguous
information in regard to it’s mechanism of function.
The biological effects of HER2
The biological effects induced by HER2 as revealed by
the phenotypic differences between R2N1d and R2d cells
and from HER2 inhibitor study include 1) the morpholo-
gical change from contact-sensitive R2d cell culture to
contact-insensitive (piling up) R2N1d cells with increas-
ing cell separation and motility (Figure 1A); 2) the devel-
opment of fast-growing invasive tumors, in contrast to
R2d cells which were non-tumorigenic (Figure 4A) [16],
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+/CD24
-/low in R2d and R2N1d cells and Modulation of HER2, Oct-4, AKT
and HDAC6 expression in R2N1 cells by cell culture condition. A, higher frequency of CD44
+/CD24
-/low cells was found in R2N1d cells than
R2d cells (~50% vs. ~10%). R1 region denotes a small population of CD44
high cells which was increased in R2N1d cells. The fluorescence cut off
level: high expression was fluorescence intensity > 10
3; negative or low expression was fluorescence intensity < 10
2. B, CD44
+/CD24
- cells sorted
by flow cytometry tend to show contact-insensitive growth in confluent culture and gave rise to non-adherent cells in suspension. By flow
cytometric analysis (C, E), and by western blotting (D), adherent cells and re-attached cells were found to be HER2
+/OCT4
+/AKT
+/HDAC6
+,
whereas non-adherent cells were HER2
-/OCT4
+/AKT
-/HDAC6
-. The length of the scale bar of these photos is 100 μm.
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tor study (Figure 3F). Unlike R2dE (R2d developed in
estrogen-containing medium) [16], the tumors developed
by R2N1d cells did not require estrogen treatment and
the resulting tumors were significantly larger. The aver-
age size of tumors developed by R2N1d cells (225 mg
and 528 mg formed by 1 × 10
6 and 1 × 10
7 cells, respec-
tively) is comparable to tumors formed by the parental
M13SV1R2N1 cells which is 295 mg and 11.2 mm in dia-
meter (formed by 6 × 10
6 cells) [28] and much larger
than tumors developed by R2dE cells (3 mm in diameter)
[16]. Other major phenotypes of R2d and R2N1d and
their parental cell lines are summarized in Additional file
4, Table S2.
Major effects of HER2 on gene expression
The comparison of gene expression profiles between
R2d and R2N1d cells by using the Human WG-6 Bead-
Chip reveals that many genes related to cell adhesion,
migration, metastasis, inflammation and angiogenesis
have been significantly activated (Table S1, Figure 2).
The enhanced expression of these genes could be the
primary effect of HER2 or secondary effect of few key
genes induced by HER2. By using the micro-array analy-
sis and other methods, i.e. qPCR, specific inhibitors,
flow cytometric and western blotting analyses, few key
genes with profound consequence in tumorigenesis have
been found to be induced by HER2. These genes include
COX-2, HDAC6 and breast cancer stem cell marker,
CD44
+/CD24
- .
COX-2 over-expression has been found in about 40%
of cases of invasive breast carcinoma and at a higher fre-
quency in preinvasive ductal carcinoma in situ (DCIS)
[42]. By qPCR analysis, the level of COX-2 transcripts
was significantly elevated in R2N1d cells (2.6 folds)
compared with R2d cells (Table 1). The expression of
COX-2 in R2N1d can be significantly decreased by
treatment with HER2 inhibitor, AG825, or MAPK/ERK
inhibitor, U0126, using flow cytometric (Figure 3A) or
western blotting (Figure 3B) analysis. Since COX-2
could promote tumor progression by inducing various
effects such as invasion, angiogenesis and suppression of
Figure 6 Tumorigenicity of 3 types of R2N1d cells in immune-deficient mice. Adherent (CD44
+/CD24
- sorted), non-adherent and re-
attached R2N1d cells were inoculated subcutaneously into nude mice for tumor development. Only those mice inoculated with adherent and
reattached R2N1d cells showed visible and palpable tumors 4 weeks after inoculation; Mice inoculated with non-adherent R2N1d cells
developed tumors after 24 weeks. Histological sections of resected tumor harvested at 4 weeks (from adherent and reattached cells) or 24 weeks
(from non-adherent cells) showed HER2 expression. The length of the scale bar of these photos is 100 μm.
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Page 10 of 15Figure 7 A diagram depicting the change in HER2 expression and tumorigenicity of R2N1d (CD44
+/CD24
- sorted) cells due to cell
culture condition. Adherent R2N1d cells were OCT4
+/HER2
+ and highly tumorigenic (tumor developed in 1 month after inoculation), the non-
adherent R2N1d cells detached from confluent R2N1d cells in suspension were OCT4
+/HER2
- and took longer time (6 months) to develop tumor
at lower frequency. The reattached R2N1d cells from non-adherent cells were similar to parental adherent cells in OCT4
+/HER2
+ expression and
tumor development.
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Page 11 of 15apoptosis as mentioned before, a major function of
HER2 in tumorigenesis could be mediated through the
up-regulation of COX-2. Since high frequency of R2N1d
cells expressed CD44 (Figure 5A) which was found to
mediate invasion [14], there could be a synergistic effect
of CD44 and COX-2 on inducing the ability of invasion
of these cells.
Unlike the parental cell lines developed in hormone/
growth factor-enriched medium (M13SV1R2 and
M13SV1R2N1) (Additional file 5, Figure S3), the R2d
and R2N1d cells developed in hormone/growth factor-
deprived medium contain CD44
+/CD24
- cells ([16] and
this study). The frequency of these cells was much
higher in R2N1d cells (~50%) than in R2d cells (~10%)
(Figure 5A). The results indicate that HER2 may sustain
tumor growth and promote distant metastasis [43] by
increasing the frequency of CD44
+/CD24
- cancer stem
cells. It is noted from our previous study [16] that R2d
cells were non-tumorigenic. However, after the exposure
to estrogen, these cells increased the expression of
CD44
+/CD24
- (from 10% to 15%) and became tumori-
genic. A previous study reported that Herceptin treat-
ment could decrease ALDH-positive cells in a HER2-
expressing breast carcinoma cell line [20]. The side
population of breast carcinoma, MCF-7, cell line was
tumorigenic and expressed high level of Notch-1 and
beta-catenin besides ABCG2, suggesting that side popu-
lation has some intrinsic properties of stem cells [44].
Recently, HER2 expression was found to increase the
frequencies of side population in both luminal and basal
subtypes of breast cancers [45]. These observations and
the results of our study using different breast cancer
stem cell markers provide independent evidence that
HER2 has the ability to maintain high frequency of
tumor stem cells.
The expression of histone deacetylase, HDAC6, was
found to be higher in R2N1d cells than R2d cells (2.41
folds) by microarray study (Additional file 1, Table S1),
although both cell lines show high expression by flow
cytometric analysis (Figure 3C). This gene can be
down-regulated by treatment with HER2 and PI3K
inhibitors (Figure 3D). Except for the regulation of cell
motility by HDAD6 via estrogen signaling [46], not
much is known about the regulation of HDAC6 in
human breast cancer. The results of this study provide
evidence that HDAC6 expression could be regulated
by HER2 and AKT1 in breast cancer. The regulation
of Akt phosphorylation by HDAC6 has been reported
[36]. Therefore, it is possible that HER2 may activate
PI3K/Akt activity through up-regulation of HDAC6.
Like COX-2, HDAC6 could induce pleiotropic effects
on tumorigenesis and tumor progression [35-39]. It
appears that both are key genes that mediate HER2
effects on tumor progression.
Modulation of HER2 expression by cell culture condition
and tumorigenesis
Non-adherent cells derived from CD44
+/CD24
- R2N1d
cells were found to lose the expression of HER2, HDAC
and AKT simultaneously (Figure 5C, D, E). Apparently,
the non-adherent cells are resistant to anoikis by a
mechanism in the absence of Akt expression [47]. After
replating and reattachment as adherent culture, these
cells regained the expression of these 3 genes. We have
carried out experiments to test the importance of the
expression of these genes in tumor development (Figure
6 and 7). The comparative study showed that non-
adherent R2N1d cells formed tumors with HER2 expres-
sion but at lower frequency (4/6 vs. 6/6) and with much
longer latency period (6 months vs. 2 weeks). The
results reaffirm the important role of HER2 in tumor
development and show that HER2 expression can be
modulated by cell culture condition.
We speculate that HER2 expression could be modu-
lated by changed in vivo condition following chemother-
apy and/or radiation treatment. The few remaining
cancer stem cells under the changed environment may
not express HER2 and remain non-tumorigenic for a
long time. However, these cells could express HER2 and
become tumorigenic in response to tissue or humoral
change. This may be a mechanism for tumor dormancy
[48] and relapse.
Overall, this study provides clear evidence that HER2
has the ability to induce fast-growing invasive breast
tumors of stem cell origin. Considering the key genes
induced by HER2 and their biological effects, it appears
that the up-regulation of the expression of COX-2 and
HDAC6, and the increase in CD44
+/CD24
- cancer stem
cell frequency may account for the potent tumorigenic
function of HER2 in breast carcinogenesis. To counter
these HER2 effects, future therapy of HER2-positive
breast tumors may consider a strategy of using the com-
bination of anti-HER2 antibodies with other drugs that
target breast cancer stem cells such as metfdormin
[49,50], salinomycin [51] and CXCR1 [52] to eliminate
breast cancer stem cells.
Methods
Development of R2d and R2N1d cells
Previously, we have reported the development of immor-
tal (M13SV1), weakly tumorigenic (M13SV1R2) and
highly tumorigenic (M13SV1R2N1) cell lines from a
human breast epithelial cell type with stem cell charac-
teristics after successive SV40 large T-antigen transfec-
tion, X-ray irradiation and ectopic expression of C-
erbB2/neu oncogene [25,28]. These M13SV1R2 cells lost
their tumorigenicity concomitant with the expression of
two tumor suppressor genes, maspin and alpha-6 integ-
rin, after culturing in a growth factor/hormone-deprived
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Page 12 of 15medium for >10 passages (referred to as R2d) [16]. In this
study, M13SV1R2N1 cells were cultured in the MSU-1
medium supplemented with growth factors/hormones
and 5% fetal bovine serum (FBS) [21]. After one week
culture in this medium, M13SV1R2N1 cells were subcul-
tured in the basic MSU-1 medium with 5% FBS without
other growth factors/hormones and passaged more than
10 times (referred to as R2N1d cells) (Figure 1A).
Immunocytochemical analysis of gene expression
For immunostaining, cells were fixed by 4% paraformal-
dehyde in phosphate buffered saline (PBS). After rinsing
with PBS, the cells were permeabilized (0.5% triton X-
100) for 10 min. These cells were then incubated with
primary antibodies (ant-HER2 or anti-ER-a)a t2 5 ℃
overnight. The following day, these cells were incubated
with a secondary antibody conjugated with fluorescein
isothiocyanate (FITC) (50 μg/ml, Sigma, USA) for 1 hr
at 25℃. For nuclear staining, the cells were washed with
PBS before incubation with 4’, 6 diamidino-2-phenylin-
dole (DAPI, Sigma, USA) (1 μg/ml in PBS) for 5 min.
Flow cytometric analysis of gene expression
Following trypsinization, cells were strained through a
40 μM nylon mesh to ensure the obtaining of single
cells and suspended in ice-cold solution for a density of
1×1 0
6 cells/ml. Antibodies (Notch-4, Msi1, Notch-1,
CK-18, CK-19, Oct-4, HDAC6, COX2 and HER2; CD24
conjugated with FITC; CD44 conjugated with phycoery-
thrin, PE) were added to the cell suspension at concen-
trations suggested by the manufacturer and cells were
incubated at 4°C in the dark for 45 min. Then the cells
were incubated with a secondary antibody conjugated
with FITC or PE for 1 hr at 4°C. These labeled cells
were washed twice, suspended in PBS and analyzed
using a flow cytometer (FACS Calibur, Becton Dickin-
son). As negative controls, cells were stained with either
isotype-matched control antibodies or with no primary
antibody. No difference was observed between these two
controls.
Western blotting
The proteins were extracted with 20% SDS lysis solution
containing several protease and phosphatase inhibitors
(1 mM phenylmethylsulfonyl fluoride, 1 mM leupeptin,
1m Ma n t i p a i n ,0 . 1m Ma p r o t i n i n ,0 . 1m Ms o d i u m
orthovanadate, 5 mM sodium fluoride). Protein concen-
trations were measured using Biorad Protein Quantifica-
tion kit (Biorad, CA, USA). Equal amounts of protein
(15 μg/lane) were separated by 12% SDS-PAGE and
transferred from the gel to PVDF membranes (Millipore
Corp, Bedford, MA). Immunoblotting was carried out
using monoclonal antibody (anti-COX-2, anti-COX-1,
anti-AKT1, anti-HER2, anti-Oct4, anti-HDAC6, anti-
alpha-tubulin and anti-b-Actin). This was then followed
by incubation with horseradish peroxidase-conjugated
secondary antibody and detected with the ECL chemilu-
minescent detection reagent (Amersham Co., IL, USA).
The membranes were exposed to X-ray film for 15 s to
3 min.
Reverse transcription-polymerase chain reaction (RT-PCR)
5 μg of total RNA extracted from cells were used to
synthesize the first-strand cDNA, using the Reverse
Transcription System (Promega, A3500) according to
the manufacturer’s protocol. PCR amplification was car-
ried out by using 1 μLo ft h ef i r s t - s t r a n dc D N Aa sa
template in a total volume of 15 μLc o n t a i n i n g1μLo f
each primer (10 pmol/L) and 7.5 μLo fE c o n o T a q®
PLUS GREEN Master Mix Kit (Lucigen, F93481-1). The
primers used are as listed for HER2 (forward, 5’-
CCCGAAACGTGCTAGTCAAGAG-3’;r e v e r s e ,5 ’-
TGCAGATTGGAGGCTGAG GTAG-3’)a n dHDAC6
(forward, 5’-CCAGCTAACCCACCTGCTCATG-3’;
reverse, 5’-GGGCTTCCAGAGCACAGGAAAC-3’). Fol-
lowing 1 minute denaturation at 95°C, the reactions
were cycled 30 times with 45 seconds denaturation at
95°C and 30 seconds annealing at 55°C and then exten-
sion at 72°C for 1 min. The reactions were performed in
the DNA Thermal Cycler 480 (Takara). The last poly-
merization step was at 72°C for 10 min.
Invasion assay
Cells were inoculated into 24-well Matrigel™ Invasion
inserts (2.5 × 10
5 cells/well) (8 μmp o r es i z e )( B DB i o s -
ciences, USA). Inserts were placed into Falcon compa-
nion plates and incubated for 24 hr for invasion.
Following incubation, media plus cells were removed
from the top chamber using cotton swabs and PBS. The
number of cells invading to the underside of the mem-
brane was determined. The data are presented as the
average number of invading cells per well in triplicate.
Tumorigenicity in SCID mice
Female immune-deficient (SCID) mice (BALB/cAnN.Cg-
Foxn1
nu/CrlNarl, 4 to 6-week-old) were obtained from
the National Laboratory Animal Center (Taipei, Tai-
wan). Different numbers of R2d, R2N1d, non-adherent
R2N1d and re-attached R2N1d cells (1 × 10
5,n=6 ;1×
10
6,n=6 ;1×1 0
7, n = 6), were inoculated subcuta-
neously into female immune-deficient (SCID) mice, 2
sites for each mouse. Tumors developed were dissected,
measured and histologically examined.
Immunohistochemical study of gene expression in tumor
tissues
Serially cut tumor sections (4 um thick) were processed
and incubated with primary antibodies against Ki-67
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Page 13 of 15(1:75), COX-2 (1:50) (Dako, Denmark), matrix metallo-
proteinase-9 (MMP-9) (1:75), (Neomarkers, USA), HER2
(Dako, Denmark) (1:75) and vascular endothelial growth
factor (VEGF) (1:150) (Santa Cruz Biotechnology, USA)
at room temperature for 1 hr. The sections were then
incubated in 3, 3-diaminobenzidine solution for 5 min,
followed by Mayer’s haematoxylin counterstaining and
mounting. Negative controls were treated with non-
immune serum instead of primary antibody.
The classification and evaluation of the expression of
pathological markers in tumor tissues were as described
[16].
Statistical analysis
Results shown are representative of at least three sepa-
rate experiments. The significance of difference
between treatments was assessed by the Mann-Whit-
ney test of nonparametric statistics and was carried
out using SPSS for Windows 13.0 statistics program
(SPSS Inc., Chicago, USA). The p value < 0.05 was
considered to be significant. All statistical data are pre-
sented as mean ± SD.
Additional material
Additional file 1: Table S1: The effects of HER2 on gene expression
in R2N1d cells as indicated by R2N1d/R2d ratio
Additional file 2: Figure S1: The HER2 effect on up-regulation of
COX2 expression is confirmed by western blot analysis when
R2N1d and R2d cells are compared.
Additional file 3: Figure S2: The expression of CD44
+/CD24
- in non-
adherent R2N1d cells was found to be dramatically reduced
compared to adherent cells.
Additional file 4: Table S2: Characteristics of M13SV1R2, R2d,
M13SV1R2N1 and R2N1d cell line.
Additional file 5: Figure S3: The parental cell lines (M13SV1R2 and
M13SV1R2N1) developed in hormone/growth factor-enriched
medium.
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